Orgenesis Stock Today
| ORGS Stock | USD 0.15 0.23 60.53% |
PerformanceSolid
| Odds Of DistressModerate
|
Orgenesis is selling for under 0.15 as of the 5th of January 2026; that is 60.53 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.15. Orgenesis has over 56 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat solid returns during the last 90 days. The performance scores are derived for the period starting the 6th of November 2025 and ending today, the 5th of January 2026. Click here to learn more.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 4.77 M outstanding shares of which 56.25 K shares are now shorted by private and institutional investors with about 2.39 trading days to cover. More on Orgenesis
Moving against Orgenesis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Orgenesis Pink Sheet Highlights
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Orgenesis [ORGS] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Orgenesis conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.77 M outstanding shares of which 56.25 K shares are now shorted by private and institutional investors with about 2.39 trading days to cover.
Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09.
Check Orgenesis Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Orgenesis is $10.07 Million. Orgenesis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Orgenesis Ownership Details
Orgenesis Risk Profiles
| Mean Deviation | 109.82 | |||
| Semi Deviation | 38.02 | |||
| Standard Deviation | 153.34 | |||
| Variance | 23512.72 |
Orgenesis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Orgenesis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Orgenesis Corporate Management
| Victor Miller | Chief Officer | Profile | |
| Osher Rheinisch | General Officer | Profile | |
| Neil CPA | S CFO | Profile | |
| Shimon Hassin | Chief Officer | Profile | |
| Efrat Kunik | Chief Officer | Profile | |
| Pierre Lammeretz | Interim Officer | Profile | |
| Evan Fishman | Chief Officer | Profile |
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.